Microbiology agreement

April 27, 2011

Magellan Biosciences has announced an agreement with Bruker to deliver microbial identification from cultures using Bruker MALDI-TOF proteomic fingerprinting, along with Magellan?s TREK-brand susceptibility tests to clinical, research and veterinary laboratory customers.

Magellan Biosciences has announced an agreement with Bruker to deliver microbial identification from cultures using Bruker MALDI-TOF proteomic fingerprinting, along with Magellan’s TREK-brand susceptibility tests to clinical, research and veterinary laboratory customers. The product offerings are expected to improve the microbiology laboratory workflow, offering fast, reliable results that enable clinicians to make more-informed treatment decisions.

“We are pleased to offer these enhanced microbiology tools that will deliver complete, actionable information to improve patient care and fight deadly drug resistance,” said Magellan president and chief executive officer, Hiroshi Uchida, PhD. “We can soon combine the MALDI Biotyper’s rapid identification of more than 2000 species of bacteria, as well as yeast and fungi, with Sensititre’s true MIC results for an expansive list of antimicrobial drugs and dilution ranges, enabling physicians to make more-precise dosing decisions.“

Under the terms of the agreement, Magellan will develop and test an integrated cross-platform software interface that will enable microbial identification information gathered on the MALDI biotyper mass spectrometry-based proteomic fingerprinting system to be combined with Magellan’s Sensititre susceptibility results. According to the companies, the software will allow laboratories to generate custom expert rules, which can guide laboratory and clinical action upon receipt of results from both systems.

“This arrangement leverages both companies’ products and experience, while providing significant improvements in ease of use and time-to-results using the MALDI Biotyper for cost-effective, proteomic fingerprint-based identification,” commented Bruker Daltonics’ vice president for Business Development, Gary Kruppa, PhD. “Bruker is committed to the Open Microbiology Consortium concepts of open interfaces, and of making its systems compatible with other microbiology products in order to provide the most advanced and cost-effective solutions to microbiology customers worldwide.”

For more information on the companies visit www.magellanbio.com and www.bdal.com

Related Content:

News